- Home
- HURN vs APLS Comparison
HURN vs APLS Comparison
Compare HURN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- APLS
- Stock Information
- Founded
- HURN 2002
- APLS 2009
- Country
- HURN United States
- APLS United States
- Employees
- HURN N/A
- APLS N/A
- Industry
- HURN Professional Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- APLS Health Care
- Exchange
- HURN Nasdaq
- APLS Nasdaq
- Market Cap
- HURN 2.6B
- APLS 2.2B
- IPO Year
- HURN 2004
- APLS 2017
- Fundamental
- Price
- HURN $142.83
- APLS $16.93
- Analyst Decision
- HURN Strong Buy
- APLS Buy
- Analyst Count
- HURN 5
- APLS 19
- Target Price
- HURN $158.60
- APLS $37.50
- AVG Volume (30 Days)
- HURN 237.5K
- APLS 2.9M
- Earning Date
- HURN 04-29-2025
- APLS 05-07-2025
- Dividend Yield
- HURN N/A
- APLS N/A
- EPS Growth
- HURN 92.74
- APLS N/A
- EPS
- HURN 6.67
- APLS N/A
- Revenue
- HURN $1,525,814,000.00
- APLS $775,839,000.00
- Revenue This Year
- HURN $11.50
- APLS $1.54
- Revenue Next Year
- HURN $7.48
- APLS $22.80
- P/E Ratio
- HURN $21.43
- APLS N/A
- Revenue Growth
- HURN 8.98
- APLS 48.04
- 52 Week Low
- HURN $85.35
- APLS $16.10
- 52 Week High
- HURN $155.00
- APLS $43.76
- Technical
- Relative Strength Index (RSI)
- HURN 45.40
- APLS 41.44
- Support Level
- HURN $136.98
- APLS $16.61
- Resistance Level
- HURN $155.00
- APLS $17.48
- Average True Range (ATR)
- HURN 4.91
- APLS 0.86
- MACD
- HURN -1.28
- APLS 0.09
- Stochastic Oscillator
- HURN 32.46
- APLS 28.47
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.